These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7000408)

  • 21. Role of monocytes, alloantigens, and individual reactivity in the response of human lymphocytes to mitogenic factor.
    Ruiz P; Scornik JC
    J Immunol; 1982 Mar; 128(3):1289-95. PubMed ID: 6460059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of uremic sera on the blastic transformation of lymphocytes of healthy subjects, stimulated with non-specific mitogens (PHA, con A, PWM).
    Klinger M; Kuczera J; Kruzel E
    Arch Immunol Ther Exp (Warsz); 1980; 28(1):73-82. PubMed ID: 7416921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro cytotoxic properties of plasma samples from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Clin Nephrol; 1982 May; 17(5):247-53. PubMed ID: 7094441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat.
    Anderstam B; Mamoun AH; Södersten P; Bergström J
    J Am Soc Nephrol; 1996 Nov; 7(11):2453-60. PubMed ID: 8959639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of unrelated HLA-identical bone marrow donors: RFLP, oligotyping and PCR fingerprinting for HLA class II compared to MLC responses.
    Mazzola G; el-Borai MH; Berrino M; Cornaglia M; Amoroso A
    Bone Marrow Transplant; 1993; 11 Suppl 1():24-7. PubMed ID: 8095414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic heparinization of uremic patients and its effects on blood lipids and on in vitro toxicity of the plasma.
    Wessel-Aas T; Christophersen B
    Clin Nephrol; 1982 Sep; 18(3):135-40. PubMed ID: 7140025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphocytes from multitransfused uremic patients have poor MLC reactivity.
    Fehrman I; Ringdén O
    Tissue Antigens; 1981; 17(4):386-95. PubMed ID: 6460343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients.
    Zimmerman L; Egestad B; Jörnvall H; Bergström J
    Clin Nephrol; 1989 Sep; 32(3):124-8. PubMed ID: 2791363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Control by means of Computer control of the hematochemical picture in chronic uremic patients undergoing periodic hemodialysis treatment].
    Novario PG; Pagliano B; Denti E; Segoloni G; Piccoli G; Vercellone A; Coppo R
    Minerva Nefrol; 1974; 21(5):347-59. PubMed ID: 4467056
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
    Dasgupta A; Jacques M
    Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Retention of medium sized molecules in uremic serum].
    Dall'aglio P; Buzio C; Cambi V; Arisi L; Migone L
    Proc Eur Dial Transplant Assoc; 1972; 9():409-16. PubMed ID: 4668919
    [No Abstract]   [Full Text] [Related]  

  • 34. Possible mechanisms by which alloantisera inhibit in the MLC test.
    Jonker M; de Rooy-Doyer L
    Tissue Antigens; 1980 Jan; 15(1):1-10. PubMed ID: 12735326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of serum and plasma from hemodialysis patients on the lymphoproliferative response.
    Miyakoshi H; Aoki T; Hirasawa Y
    Clin Nephrol; 1979 Dec; 12(6):263-8. PubMed ID: 527279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral immunity in renal transplantation Detection of cytotoxic antibodies to lymphocyte antigens other than HLA-A,B,C and Ia-like antigens in patients with vascular graft rejection.
    Lordon RE; Wilson RL; Shield CF; Ferrone S
    Transplantation; 1981 Oct; 32(4):286-90. PubMed ID: 7036445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
    Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
    J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
    Dasgupta A; Jacques M; Malhotra D
    Am J Nephrol; 1996; 16(4):327-33. PubMed ID: 8739287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specificity of the inhibitory effect of a grand-multipara serum on MLC reactions and on responses to PHA, PWM and PPD.
    Herva E; Ilonen J
    Acta Pathol Microbiol Scand C; 1977 Dec; 85C(6):424-34. PubMed ID: 75658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of uremic serum on E-rosette formation of normal lymphocytes modulated by levamisole.
    Modai D; Peller S; Weissgarten J; Shaked U; Kaufman S
    Isr J Med Sci; 1981 Dec; 17(12):1115-8. PubMed ID: 7327910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.